| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8531917 | Journal of the American Pharmacists Association | 2018 | 7 Pages |
Abstract
Collaboration between providers and an LSP minimized delay in therapy, lowered rates of DAA denial, facilitated patient financial assistance, and helped to optimize clinical outcomes. The PP-SVR rate for this study was similar to rates reported in the literature and higher than expected, considering the inclusion of earlier-generation DAAs and many patients with advanced liver disease.
Related Topics
Health Sciences
Medicine and Dentistry
Public Health and Health Policy
Authors
Julia Zhu, Ronald J. Hazen, Cara Joyce, Ambrose Delpino, Heather S. Kirkham, Carson Dietrich Strickland, Shauna Markes-Wilson, Tomeka Kim, Meen Kang, Raymond A. Rubin, Lance L. Stein,